UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Temozolomide as second-line chemotherapy for relapsed gliomas

Trent, S; Kong, A; Short, SC; Traish, D; Ashley, S; Dowe, A; Hines, F; (2002) Temozolomide as second-line chemotherapy for relapsed gliomas. Journal of Neuro-Oncology , 57 (3) pp. 247-251.

Full text not available from this repository.

Abstract

Background: Temozolomide, an imidazotetrazine prodrug has shown activity in phase II studies in patients with high-grade glioma at first recurrence. We assessed the efficacy of temozolomide as second-line therapy following failure of PCV chemotherapy in patients with recurrent/progressive gliomas. Patients and methods: Between September 1994 and November 2000, 32 patients with high-grade gliomas at second recurrence/progression received temozolomide as salvage therapy and results were reviewed retrospectively. Results: Of 32 assessable patients 7 had clinical improvement; there were no imaging responses. Median survival of the cohort was 4 months, with 28% alive at 6 months. Age, performance status, histology and previous response to PCV chemotherapy did not predict for clinical response to temozolomide. Conclusion: In the small cohort of patients with recurrent malignant glioma who failed PCV chemotherapy temozolomide demonstrated limited activity as second-line treatment although this remains within the confidence intervals of response seen in patients with glioblastoma

Type: Article
Title: Temozolomide as second-line chemotherapy for relapsed gliomas
Additional information: Journal English Article KLUWER ACADEMIC PUBL MAY 571TD DORDRECHT Brada M Inst Canc Res & Royal Marsden NHS Trust, Neuro Oncol Unit, Downs Rd, Sutton SM2 5PT, Surrey, England J NEURO-ONCOL VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
Keywords: 1994, activity, age, ANAPLASTIC ASTROCYTOMA, As, Chemotherapy, clinical, COHORT, confidence, confidence interval, Confidence Intervals, Down, EFFICACY, English, FAILURE, GLIOBLASTOMA-MULTIFORME, Glioma, Histology, imaging, IMPROVEMENT, M, Malignant, May, Methods, Netherlands, NHS, November, Patient, patients, performance, phase, PHASE II, PHASE-II, PHASE-II TRIAL, PRODRUG, RD, Recurrence, RECURRENT, recurrent glioma, response, RESPONSES, Result, Royal, Salvage Therapy, September, small, SURVIVAL, temozolomide, THERAPIES, therapy, treatment, Trust, unit
UCL classification: UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Oncology
URI: http://discovery.ucl.ac.uk/id/eprint/29516
Downloads since deposit
0Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item